| Name | Title | Contact Details |
|---|
Cadence Science is a New Hyde Park, NY-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Feinstein Kean Healthcare is one of the leading providers in Healthcare, Pharmaceuticals, & Biotech. It is based in Cambridge, MA. To find more information about Feinstein Kean Healthcare, please visit www.fkhealth.com
Bringing Together the Heart and Science of Medical Management Genex was founded in 1978 with the same directive it operates under today — helping injured workers return to their jobs in a safe and efficient manner through compassionate case management, thus reducing health care costs and disability expenses for our customers. Our medical and business professionals provide comprehensive care management and multicultural services from locations across the United States and Canada.
"Eleven uses its proprietary technology platform to create first-of-a-kind protein therapeutics to address unmet needs for ophthalmic diseases. Proteins are able to modulate inflammatory cytokines, key targets in ocular disease that have been difficult to access with conventional therapeutic approaches. A significant untapped opportunity exists for protein therapeutics to address ophthalmic diseases, and Eleven is applying its advanced protein technology and expertise to develop innovative medicines for patients suffering from ocular diseases. Eleven`s team of industry veterans has deep experience in understanding protein science and biologic drug development, designing and conducting clinical trials and, most importantly, applying specific expertise in ophthalmic disease to create novel ocular therapeutics to treat unmet medical needs. Eleven has developed a proprietary pipeline of ophthalmic drug candidates derived from the company`s innovative AMP-Rx protein engineering technology. The company`s initial product candidates are focused on targeting inflammatory cytokines and key targets of ocular disease by blocking the cytokines and modulating the biological processes that drive ocular disease. Current pipeline opportunities include ocular surface diseases such as dry eye disease (DED) and allergic conjunctivitis (AC), and back of the eye diseases such as diabetic macular edema (DME) and uveitis. In addition, Eleven’s proprietary technology has been utilized to prolong the intravitreal half-life of our pipeline products. Beyond its internal drug development programs, Eleven works with collaborators, such as ThromboGenics, to apply its innovative protein therapeutic design capabilities to engineer and develop biotherapeutic products for additional therapeutic targets. EBI-005, Eleven`s lead product candidate, is a novel interleukin-1 (IL-1) receptor antagonist in Phase 3 clinical development as one of the first topically administered proteins for the treatment of DED and AC, two inflammatory diseases at the surface of the eye."
Affinity Medical Technology, LLC is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, & Biotech sector.